Inhibitors of janus kinases and infection in patients of rheumatologic profile
https://doi.org/10.33667/2078-5631-2020-31-21-26
Abstract
In recent decades, there has been clear progress in rheumatology associated with the introduction of genetically engineered biological drugs, as well as targeted basic anti-inflammatory drugs (tBPVP), which include Janus kinase inhibitors. At the same time, the use of these drugs is associated with an increasing risk of developing infections of various nature and localization, as well as reactivation of latent infection. In addition, cases of severe infections, including fatal ones, are registered. This review analyzes the literature data, mainly from the last 5 years, concerning the frequency and localization of major comorbid infections in patients with rheumatoid arthritis and psoriatic arthritis in the treatment of various tBPVS (tofacitinib, baricitinib, upadacitinib). The significance of infections (tuberculosis, herpes-viral infections, chronic viral hepatitis B) in the management of these patients is characterized. The need for a wider use of various vaccines (primarily anti-pneumococcal and anti-influenza) in patients with immuno-inflammatory rheumatic diseases is emphasized.
About the Authors
B. S. Belov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Moscow
Russian Federation
Moscow
N. V. Muravyova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Moscow
Russian Federation
Moscow
G. M. Tarasova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Moscow
Russian Federation
Moscow
M. M. Baranova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008; 26 (5 Suppl 51): 35-61.
2. Belov B. S., Balabanova R. M., Manukyan S. G., i dr. Komorbidnye infekcii pri revmaticheskih zabolevaniyah. XVI Ross. nac. kongr. «Chelovek i lekarstvo»: Tez. dokl. M., 2007. S. 527. (In Russ.).
3. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002; 46 (9): 22872293.
4. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002; 46 (9): 2294-2300.
5. van der Veen MJ., van der Heide A., Kruize AA., Bijlsma JWJ. Infection rate and use antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann. Rheum. Dis., 1994; 53: 224-228.
6. Kao LT, Lee CZ, Liu SP, et al. Psoriasis and the risk of pneumonia: a population-based study. PLoS One. 2014; 9 (12): e116077. DOI: 10.1371/journal.pone.0116077
7. Haddad A, Li S, Thavaneswaran A, et al. The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. J Rheumatol. 2016; 43 (2): 362-6. DOI: 10.3899/jrheum.140067.
8. Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct; 6 (3): e001395. DOI: 10.1136/rmdopen-2020-001395.
9. Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020 Oct; 79 (10): 1290-1297. DOI: 10.1136/annrheumdis-2019-216852.
10. Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020 Oct 28: annrheumdis-2020-218510. DOI: 10.1136/annrheumdis-2020-218510.
11. Novye rekomen-dacii VOZ po profilaktike tuberkuleza priz-vany spasti milliony zhiznej. 24 marta 2020 g. Press-reliz. Geneva. (In Russ.). Available at: https://www.who.int/ru/news/item/24-03-2020-new-who-recommendations-to-prevent-tuberculosis-aim-to-save-millions-of-lives.
12. Lukina G. V., Borisov S. E. Skrining i monitoring tuberkuleznoj infekcii u bol’nyh revmaticheskimi zabolevani-yami, poluchayushchimi genno-inzhenernye biologicheskie preparaty. V kn. Rossijskie re-komendacii. Revmatologiya. Pod red. E. L. Nasonova.M., GEOTAR-Media, 2017. S. 394-410. (In Russ.).
13. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Oct; 66 (10): 2675-84. DOI: 10.1002/art.38745.
14. Burmester GR, Curtis JR, Yun H, et al. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020 Apr; 43 (4): 379-392. DOI: 10.1007/s40264-020-00904-9.
15. Atzeni F, Talotta R, Nucera V, et al. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. Expert Rev Clin Immunol. 2018; 14 (11): 945-956. DOI: 10.1080/1744666X.2018.1504678.
16. Almanzar G, Kienle F, Schmalzing M et al. To-facitinib modulates the VZV-specific CD 4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis. Rheumatology. 2019; 58 (11): 2051-2060. DOI: 10.1093/rheumatology/kez175.
17. Chen YM, Huang WN, Wu YD, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofaci-tinib: a real-world study. Ann Rheum Dis. 2018; 77 (5): 780-782. DOI: 10.1136/annrheum-dis-2017-211322.
18. Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020 Feb; 6 (1): e001095. DOI: 10.1136/rm-dopen-2019-001095.
19. Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020 Mar 16; 12:1759720X20912646. DOI: 10.1177/1759720X20912646.
20. Furer V, Rondaan C, Heijstek MW et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.Ann Rheum Dis. 2020 Jan; 79 (1): 39-52. DOI: 10.1136/ann-rheumdis-2019-215882.
21. Baumrin E, van Voorhees A, Garg A, et al. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019 Jul; 81 (1): 102-110. DOI: 10.1016/j.jaad.2019.03.017.
Review
For citations:
Belov B.S., Muravyova N.V., Tarasova G.M., Baranova M.M. Inhibitors of janus kinases and infection in patients of rheumatologic profile. Medical alphabet. 2020;(31):21-26. (In Russ.) https://doi.org/10.33667/2078-5631-2020-31-21-26
Views:
393
Email this article 